Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are currently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $173.25.

RGEN has been the topic of several research reports. Wall Street Zen upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Thursday, May 8th. Evercore ISI initiated coverage on Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. JPMorgan Chase & Co. decreased their target price on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Finally, Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a research report on Tuesday, April 29th.

Repligen Stock Up 0.9%

Shares of RGEN opened at $132.87 on Wednesday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The stock’s 50 day moving average is $127.51 and its two-hundred day moving average is $143.27. The firm has a market cap of $7.47 billion, a P/E ratio of -260.53, a PEG ratio of 4.54 and a beta of 1.10.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $0.28 earnings per share. Analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently added to or reduced their stakes in the stock. Osterweis Capital Management Inc. lifted its position in Repligen by 18.0% during the first quarter. Osterweis Capital Management Inc. now owns 72,765 shares of the biotechnology company’s stock worth $9,259,000 after buying an additional 11,080 shares in the last quarter. Strs Ohio acquired a new stake in Repligen during the first quarter worth $6,069,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Repligen by 7.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,497 shares of the biotechnology company’s stock worth $32,128,000 after acquiring an additional 17,154 shares during the last quarter. Woodline Partners LP acquired a new stake in Repligen during the first quarter worth $7,152,000. Finally, United Services Automobile Association acquired a new stake in Repligen during the first quarter worth $461,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.